Hypertrophic cardiomyopathy surgery

Hypertrophic Cardiomyopathy Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hypertrophic Cardiomyopathy from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Interventions
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hypertrophic cardiomyopathy surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hypertrophic cardiomyopathy surgery
CDC on Hypertrophic cardiomyopathy surgery
Hypertrophic cardiomyopathy surgery in the news
Blogs on Hypertrophic cardiomyopathy surgery
Directions to Hospitals Treating Hypertrophic cardiomyopathy
Risk calculators and risk factors for Hypertrophic cardiomyopathy surgery

Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1], Cafer Zorkun, M.D. [2], Caitlin J. Harrigan [3], Martin S. Maron, M.D., and Barry J. Maron, M.D.

Cardiac transplantation

Cardiac transplantation can be performed in patients with HOCM and has been associated with better post-operative survival than those patients transplanted for ischemic cardiomyopathy .

In cases that are refractory to all other forms of treatment, cardiac transplantation is an option.

2011 ACCF/AHA Guideline Recommendations for Selection of Patients for Heart Transplantation (DO NOT EDIT)

Class I

"1. Patients with advanced heart failure (end stage) and nonobstructive HCM not otherwise amenable to other treatment interventions, with EF less than or equal to 50% (or occasionally with preserved EF), should be considered for heart transplantation. (Level of Evidence: B) "

"2. Symptomatic children with HCM with restrictive physiology who are not responsive to or appropriate candidates for other therapeutic interventions should be considered for heart transplantation. (Level of Evidence: C)"

Class III (Harm)

"1. Heart transplantation should not be performed in mildly symptomatic patients of any age with HCM. (Level of Evidence: C) "